Oligomannate, derived from a compound in seaweed, suppresses neural inflammation caused by gut bacteria in mice.

On Saturday (November 2), Chinese regulators approved a drug to treat Alzheimer’s disease—the first new treatment to enter the global market in 17 years. Shanghai Green Valley Pharmaceuticals’s oligomannate boosted cognitive function among clinical trial participants who had mild to moderate Alzheimer’s as early as a month after taking the drug, compared with those who took a placebo.

CC0 Creative Commons, Pixabay

Read more…